The news has been littered this year with reports of disappointing clinical trials of promising drugs intended to alter the course of Alzheimer’s disease. But researchers are plugging on, and sometime in the foreseeable future they may have a new tool to help them. A startup called Neurotrack is commercializing a sophisticated computer-based diagnostic tool […]
The U.S. will continue to lead the global vaccine market and grow as much as 5.3 percent each year until 2018, according to a new report from Transparency Market Research. With the potential to reach $17.4 billion by 2018, the market is moving toward consolidation, with the most dominant players being Pfizer, GSK, Novartis and […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A clinical stage drug company developing a disease-modifying Alzheimer's drug has quietly secured more than $4M in nonequity financing since its $30M series A.
It’s no secret that most seniors today prefer to “age in place” — and healthcare innovators hear that loud and clear. But despite patients’ preferences, chronic illnesses that cause many seniors to require care that’s difficult to provide at home aren’t going away any time soon. Nursing homes and assisted-living facilities face unique challenges in […]
Alzheimer's disease can't be prevented or cured, and it ranks second only to cancer among diseases that people fear. Still, a study last year found that about two-thirds of respondents would want to know if they were destined to get the disease. Al...
Cardinal Health (NYSE:CAH) will manufacture and distribute a radioactive imaging agent from Eli Lilly (NYSE:LLY) that could help doctors diagnose Alzheimer’s disease. The imaging agent, called Amyvid, is scheduled for commercial launch on June 1, according to a statement from Dublin, Ohio-based Cardinal. Amyvid was approved by the U.S. Food and Drug Administration in April. […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Targacept’s (NASDAQ:TRGT) drug development effort is focused on the here, now and soon to be future. It has to be because a corporate restructuring that will lead to layoffs of 65 workers — nearly half of Targacept employees — has had particular impact on the company’s preclinical research. That means Targacept will need to […]
Targacept‘s (NASDAQ:TRGT) first quarter dealt the company several blows with a phase 3 clinical trial failure for its lead drug candidate and a missed target in another clinical program. Failure of depression candidate TC-5214 led to the formal termination of the company’s partnership with AstraZeneca (NYSE:AZN) on that compound. Rights to TC-5214 revert to Targacept […]
Researchers from Case Western Reserve University made a big splash earlier this year when they published research that showed a skin cancer drug reversed Alzheimer’s disease in mice. Now, the researchers have formed a company, ReXceptor, to begin tests that could determine whether the already approved cancer drug, called bexarotene (brand name Targretin), could have […]
A company has acquired a DNA vaccine for Alzheimer’s disease that is designed to trigger an immune response to the disease. The vaccine, in preclinical development, differs from other Alzheimer’s vaccines under study in that it only contains a piece of the coding for the amyloid beta protein, a company statement said. Amyloid beta in […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Eli Lilly (NYSE:LLY) said Friday that the FDA approved Amyvid, its radioactive diagnostic imaging agent to help diagnose Alzheimer’s disease and other causes of cognitive decline. Amyvid binds to beta amyloid plaques, which are characteristic of Alzheimer’s and other neurological conditions, and appears in PET scan images of the brain. According to Lilly, the agent […]
LabCorp (NYSE:LH) has struck a deal to develop and commercialize a new Alzheimer’s disease diagnostic. The Burlington, North Carolina lab services and diagnostics company has licensed rights to an Alzheimer’s diagnostic technology from OPKO Health (NYSE:OPK). The deal gives LabCorp exclusive rights to the OPKO technology in North America and the United Arab Emirates. No […]
In the world of the pharma patent cliff, Eli Lilly & Co. (NYSE:LLY) stands in a particularly vulnerable spot. As the drugmaker awaits clinical trial results from a late-stage Alzheimer’s candidate, company leaders are faced with reports of decreasing revenue and more patent expirations. They are crossing their fingers that solanezumab, which most analysts lack […]
A drug that’s already approved by the FDA has shown promise in clearing away a plaque in the brain that’s associated with Alzheimer’s disease, Case Western Reserve University researchers have found. The drug, bexarotene (brand name Targretin), in mice was able to reduce levels of Beta-amyloid plaque, a protein fragment that builds up in the […]
Drug developer Curaxis Pharmaceutical (PINK:CURX) aims to find a drug partner this year who could help the cash-strapped company resume clinical trials on its experimental Alzheimer’s disease treatment. Curaxis Chairman and interim CEO Timothy Wright said in a letter to shareholders that the company is focused on attracting bridge financing between $1 million and $2 […]